



PATENT
Attorney Docket No. 056291-5188

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Ingemar STARKE et al.**) Confirmation No.: **4986**
Application No.: **10/518,010**) Group Art Unit: **1624**
Filed: **December 14, 2004**) Examiner: **Coleman, Brenda Libby**
For: **PEPTIDES DERIVATIVES COMPRISING**)
THIAZEPINE GROUP FOR THE)
TREATMENT OF HYPERLIPIDEMIC)
CONDITIONS)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Starke et al.	10/220,877 March 5, 2001	6,906,058 June 14, 2005	WO 01/66533 September 13, 2001
Starke et al.	10/399,336 September 16, 2003		WO 02/32428 April 25, 2002
Starke et al.	10/451,262 June 20, 2003		WO 02/50051 June 27, 2002
Starke et al.	10/488,540 July 23, 2004		WO 03/020710 March 13, 2003
Starke et al.	10/489,009 October 8, 2004		WO 03/022825 March 20, 2003
Starke et al.	10/489,010 October 21, 2004		WO 03/022830 March 20, 2003
Starke et al.	10/488,870 October 7, 2004		WO 03/022286 March 20, 2003
Lindqvist	10/502,355 February 4, 2005		WO 03/061663 July 31, 2003

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Starke et al.	10/511,984 October 21, 2004		WO 03/091232 November 6, 2003
Anderberg et al.	10/520,939 January 12, 2005		WO 2004/006899 January 22, 2004

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449 form. This Supplemental Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action or a Notice of Allowance. The Commissioner is hereby authorized to charge \$180.00, as specified by §1.17(p), to Deposit Account No. 50-0310 for this Supplemental Information Disclosure Statement under the provisions of 37 C.F.R. §1.97(c).


With the exception of a published U.S. Application, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: December 30, 2005
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5188		Application No. 10/518,010	
PTO Form 1449				Applicants: Ingemar STARKE et al.			
Filing Date: December 14, 2004				Group Art Unit: 1624			

OIPE
 DEC 30 2005
 PATENT & TRADEMARK OFFICE


PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1. US 2002/142054	10/3/2002	Marlett et al.	424	738	September 10, 2001	

FOREIGN PATENT DOCUMENTS							
Document No.	Date	Country	Class	Sub-Class	Translation		
2. DE 19825804	12/16/1999	DE					
3. EP 0372542	6/13/1990	EP					
4. EP 0864582	9/16/1998	EP					
5. GB 2,262,888	7/7/1993	GB					
6. WO 93/16055	8/19/1993	WIPO					
7. WO 94/18183	8/18/1994	WIPO					
8. WO 94/18184	8/18/1994	WIPO					
9. WO 96/05188	2/22/1996	WIPO					
10. WO 96/08484	3/21/1996	WIPO					
11. WO 96/16051	5/30/1996	WIPO					
12. WO 97/33882	9/18/1997	WIPO					
13. WO 98/38182	9/3/1998	WIPO					
14. WO 98/40375	9/17/1998	WIPO					
15. WO 99/01149	1/14/1999	WIPO					
16. WO 99/32478	7/1/1999	WIPO					
17. WO 99/35135	7/15/1999	WIPO					
18. WO 99/64409	12/16/1999	WIPO					
19. WO 99/64410	12/16/1999	WIPO					
20. WO 00/01687	1/13/2000	WIPO					
21. WO 00/38725	7/6/2000	WIPO					
22. WO 00/38726	7/6/2000	WIPO					
23. WO 00/38727	7/6/2000	WIPO					
24. WO 00/38728	7/6/2000	WIPO					
25. WO 00/38729	7/6/2000	WIPO					
26. WO 00/47568	8/17/2000	WIPO					
27. WO 00/61568	10/19/2000	WIPO					
28. WO 00/62810	10/26/2000	WIPO					
29. WO 01/60807	8/23/2001	WIPO					
30. WO 01/66533	9/13/2001	WIPO					
31. WO 01/68096	9/20/2001	WIPO					
32. WO 01/68637	9/20/2001	WIPO					
33. WO 02/08211	1/31/2002	WIPO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5188		Application No. 10/518,010	
PTO Form 1449				Applicants: Ingemar STARKE et al.		Filing Date: December 14, 2004	
Group Art Unit: 1624							



U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	34.	WO 02/32428	4/25/2002	WIPO			
	35.	WO 02/50051	6/27/2002	WIPO			
	36.	WO 02/53548	7/11/2002	WIPO			Y (Abstract)
	37.	WO 03/020710	3/13/2003	WIPO			
	38.	WO 03/022286	3/20/2003	WIPO			
	39.	WO 03/022825	3/20/2003	WIPO			
	40.	WO 03/022830	3/20/2003	WIPO			
	41.	WO 03/061663	7/31/2003	WIPO			
	42.	WO 03/091232	11/6/2003	WIPO			
	43.	WO 03/106482	12/24/2003	WIPO			
	44.	WO 2004/006899	1/22/2004	WIPO			
	45.	WO 2004/076430	9/10/2004	WIPO			
	46.	WO 2004/089350	10/21/2004	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	47. Govers et al., (1994) "Characterization of the adsorption of conjugated and unconjugated bile acids to insoluble, amorphous calcium phosphate" Journal of Lipid Research, 35(5): 741-748
	48. Higaki et al., (1998) "Inhibition of Ileal Na ⁺ /Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits" Atherosclerosis, Thrombosis, and Vascular Biology 18(8): 1304-1311
	49. Ishibashi et al., (1993) "Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery" Journal of Clinical Investigation 92(2): 883-893
	50. Lewis et al., (1995) "Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice" Journal of Lipid Research, 36(5): 1098-1105
	51. Plump et al., (1992) "Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells" Cell 71(2):343-353
	52. Schiller (2001) "The therapy of constipation" Alimentary Pharmacology and Therapeutics 15(6): 749-763
	53. Sprong et al., (2002) "Dietary Calcium Phosphate Promotes Listeria monocytogenes Colonization and Translocation in Rats Fed Diets Containing Corn Oil but Not Milk Fat" J. Nutrition (US) 132(6): 1269-1274
	54. Van Tilburg et al., (1989) "Na ⁺ -dependent bile acid transport in the ileum: The balance between diarrhea and constipation" Gastroenterology 98(1): 25-32
	55. Welberg et al., (1991) "Calcium and the prevention of colon cancer" Scandinavian J. Gastroenterology Suppl Norway 188: 52-59

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.